

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SUBSTITUTE FOR FORM 1449/PTO		ATTY. DOCKET NO.: AH01646K	SERIAL NO.: 10:537,864
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE AS MANY SHEETS AS NECESSARY)		APPLICANT: Mattson <i>et al.</i>	
		FILING DATE: 06/07/2005	GROUP: 1647

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	CITE NO.	DOCUMENT NUMBER	PUB. DATE.	NAME OF PATENTEE OR APPLICANT	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/RMD/	AA	5,843,678	Dec. 1, 1998	Boyle	
	AB	6,017,729	Jan. 25, 2000	Anderson <i>et al.</i>	
	AC	6,242,213 B1	June 5, 2001	Anderson	
	AD	6,242,586 B1	June 5, 2001	Gorman <i>et al.</i>	
	AE	6,316,408 B1	Nov. 13, 2001	Boyle	
	AF	US 2002/0081720 A1	June 27, 2002	Dougall <i>et al.</i>	
	AG	US 2002/0086826 A1	July 4, 2002	Anderson <i>et al.</i>	
	AH	US 2002/0086827 A1	July 4, 2002	Anderson	
	AI	6,419,929 B1	July 16, 2002	Anderson	
	AJ	US 2002/0169117 A1	Nov. 14, 2002	Maraskovsky	
	AK	6,525,180 B1	Feb. 25, 2003	Gorman <i>et al.</i>	
	AL	US 2003/0175840 A1	Sept. 18, 2003	Anderson <i>et al.</i>	
	AM	US 2003/0176647 A1	Sept. 18, 2003	Yamaguchi <i>et al.</i>	
	AN	US 2003/0198640 A1	Oct. 23, 2003	Yu <i>et al.</i>	
	AO	US 2003/0208045 A1	Nov. 6, 2003	Yamaguchi <i>et al.</i>	
/RMD/	AP	6,645,500 B1	Nov. 11, 2003	Halkier <i>et al.</i>	

Examiner signature:	Date considered:
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RMD/ (05/15/2009)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SUBSTITUTE FOR FORM 1449/PTO			ATTY. DOCKET NO.: AH01646K		SERIAL NO.: 10/537,864
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			APPLICANT: Mattson <i>et al.</i>		
			FILING DATE: 06/07/2005		GROUP: 1647
(USE AS MANY SHEETS AS NECESSARY)					
U.S. PATENT DOCUMENTS					
*EXAMINER INITIAL	CITE NO.	DOCUMENT NUMBER	PUB. DATE	NAME OF PATENTEE OR APPLICANT	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/RMD/	AQ	US 2005/0003391 A1	Jan. 6, 2005	Anderson	
/	AR	US 2005/0003457 A1	Jan. 6, 2005	Yamaguchi <i>et al.</i>	
/	AS	US 2005/0147611 A1	July 7, 2005	Boyle <i>et al.</i>	
/	AT	US 2005/0208580 A1	Sept. 22, 2005	Yamaguchi <i>et al.</i>	
/	AU	US 2007/0009520 A1	Jan 11, 2007	Yamaguchi <i>et al.</i>	
/RMD/	AV	7,192,718 B2	Mar. 20, 2007	Yamaguchi <i>et al.</i>	
Examiner signature:				Date considered:	
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RMD/ (05/15/2008)					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

SUBSTITUTE FOR FORM 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(USE AS MANY SHEETS AS NECESSARY)

ATTY. DOCKET NO.: AH01646K	SERIAL NO.: 10/537,864
APPLICANT: Mattson <i>et al.</i>	
FILING DATE: 06/07/2005	GROUP: 1647

FOREIGN PATENT DOCUMENTS

*EXAMINER INITIAL	CITE NO. ¹	DOCUMENT NUMBER	PUB. DATE.	NAME OF PATENTEE OR APPLICANT	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
/RMD/	AW	WO 96/14328	May 17, 1996	Human Genome Sciences, Inc.		
/	AX	WO 97/23614	July 3, 1997	Amgen Inc.		
	AY	WO 98/25958	June 18, 1998	Schering Corporation		
	AZ	WO 98/28424	July 2, 1998	Immunex Corporation		
	BA	WO 98/28426	July 2, 1998	Immunex Corporation		
	BB	WO 98/46751	Oct. 22, 1998	Amgen Inc.		
	BC	WO 00/08139	Feb. 17, 2000	Human Genome Sciences, Inc.		
	BD	WO 00/15807 A1	March 23, 2000	M & E Biotech A/S		
	BE	WO 01/03719 A2	Jan. 18, 2001	Amgen Inc.		
	BF	WO 01/23549 A1	April 5, 2001	University of Western Australia		
/RMD/	BG	WO 02/04643 A1	Jan. 17, 2002	Human Genome Sciences, Inc.		
Examiner signature:				Date considered: ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RMD/ (05/15/2006)		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14.
 This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-796-9199) and select option 2.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SUBSTITUTE FOR FORM 1449/PTO		ATTY. DOCKET NO.: AH01646K	SERIAL NO.: 10,537,864
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE AS MANY SHEETS AS NECESSARY)		APPLICANT: Mattson <i>et al.</i>	
		FILING DATE: 06/07/2005	GROUP: 1647
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
Examiner initials*	Cite no. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/RMD/	BH	ANDERSON <i>et al.</i> , "A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function" <i>Nature</i> , 390(6656) :175-179 (1997)	
	BI	BAX <i>et al.</i> , "Stimulation of osteoclastic bone resorption by hydrogen peroxide", <i>Biochemical and Biophysical Research Communications</i> , 183(3) :1153-1158 (1992)	
	BJ	BERTOLINI <i>et al.</i> , "Stimulation of bone resorption and inhibition of bone formation <i>in vitro</i> by human tumour necrosis factors", <i>Nature</i> , 319 :516-518 (1986)	
	BK	BOLIN <i>et al.</i> , "HNMP-1: A Novel Hematopoietic and Neural Membrane Protein Differentially Regulated in Neural Development and Injury", <i>The Journal of Neuroscience</i> , 17(14) :5493-5502 (1997)	
	BL	CHAMBERS, T. J., "Regulation of the differentiation and function of osteoclasts", <i>Journal of Pathology</i> , 192(1) :4-13 (2000)	
	BM	COLLIN <i>et al.</i> , "Constitutive expression of osteoclast-stimulating activity by normal clonal osteoblast-like cells: effects of parathyroid hormone and 1,25-dihydroxyvitamin D3" <i>Endocrinology</i> , 131(3) :1181-1187 (1992)	
	BN	CUNNINGHAM <i>et al.</i> , "Receptor and Antibody Epitopes in Human Growth Hormone Identified by Homolog-Scanning Mutagenesis" <i>Science</i> , 243 :1330-1336 (1989)	
	BO	HALL <i>et al.</i> , "The Role of Reactive Oxygen Intermediates in Osteoclastic Bone Resorption", <i>Biochemical and Biophysical Research Communications</i> , 207(1) :280-287 (1995)	
	BP	HUGHES <i>et al.</i> , "Genetic linkage of familial expansile osteolysis to chromosome 18q", <i>Hum. Mol. Genet.</i> , 3(2) :359-361 (1994)	
/RMD/	BQ	International Search Report, International Application No. PCT/US03/39292, Applicant: Schering-Plough Ltd.; dated September 17, 2007	
Examiner signature:		Date considered:	
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RMD/ (05/15/2008)			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SUBSTITUTE FOR FORM 1449/PTO		ATTY. DOCKET NO.: AH01646K	SERIAL NO.: 10/537,864
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE AS MANY SHEETS AS NECESSARY)		APPLICANT: Mattson <i>et al.</i>	
		FILING DATE: 06/07/2005	GROUP: 1647
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
Examiner initials*	Cite no.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
/RMD/	BR	JIMI <i>et al.</i> , "Osteoclast function is activated by osteoblastic cells through a mechanism involving cell-to-cell contact", <i>Endocrinology</i> , 137 (5):2187-2190 (1996)	
	BS	KEARNS <i>et al.</i> , "RANKL and OPG Regulation of Bone Remodeling in Health and Disease", <i>Endocr. Rev.</i> , pp. 1-84; Rapid Electronic Publication first published on Dec 5, 2007 as doi:10.1210/er.2007-0014	
	BT	KHOSLA, S., "Minireview: The OPG/RANKL/RANK System", <i>Endocrinology</i> , 142 (12): 5050-5055 (2001)	
	BU	KUKITA and KUKITA, "Invited Review. Osteoclast differentiation antigen", <i>Histology and Histopathology</i> , 11 :821-830 (1996)	
	BV	LACEY <i>et al.</i> , "Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation", <i>Cell</i> , 93 (2):165-176 (1998)	
	BW	LIBERMANN and BALTIMORE, "Activation of interleukin-6 gene expression through the NF-kappa B transcription factor", <i>Mol. Cell. Biol.</i> , 10 (5):2327-2334 (1990)	
	BX	MARIE <i>et al.</i> , "In vitro production of cytokines by bone surface-derived osteoblastic cells in normal and osteoporotic postmenopausal women: relationship with cell proliferation", <i>J Clin Endocrinol Metab</i> , 77 (3):824-830 (1993).	
	BY	MC HUGH <i>et al.</i> , "Receptor activator of NF- κ B ligand arrests bone growth and promotes cortical bone resorption in growing rats", <i>J Appl Physiol</i> 95 : 672-676 (2003)	
	BZ	MEE <i>et al.</i> , "Dogs, Distemper and Paget's Disease", <i>BioEssays</i> , 15 (12):783-789 (1993)	
	CA	O'DOWD <i>et al.</i> , "Site-directed mutagenesis of the cytoplasmic domains of the human beta 2-adrenergic receptor. Localization of regions involved in G protein- receptor coupling", <i>J. Biol. Chem.</i> , 263 (31):15985-15992 (1988)	
	CB	PACIFICI <i>et al.</i> , "Spontaneous Release of Interleukin 1 from Human Blood Monocytes Reflects Bone Formation in Idiopathic Osteoporosis", <i>PNAS</i> , 84 (13): 4616-4620 (1987)	
	CC	PACIFICI <i>et al.</i> , "Effect of Surgical Menopause and Estrogen Replacement on Cytokine Release from Human Blood Mononuclear Cells", <i>PNAS</i> , 88 (12): 5134-5138 (1991)	
	CD	SCHOPPET <i>et al.</i> , "RANK Ligand and Osteoprotegerin: Paracrine Regulators of Bone Metabolism and Vascular Function", <i>Arterioscler Thromb Vasc Biol.</i> , 22 :549-553 (2002); published online before print January 31 2002, doi:10.1161/01.ATV.0000012303.37971.DA	
/RMD/	CE	SIMONET <i>et al.</i> , "Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density" <i>Cell</i> , 89 (2):309-319 (1997)	
Examiner signature:		Date considered:	
ALL REFERENCES CONSIDERED EXCEPT WHERE		LINED THROUGH. /RMD/ (05/15/2008)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. SUBSTITUTE FOR FORM 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(USE AS MANY SHEETS AS NECESSARY)

ATTY. DOCKET NO.:

AH01646K

SERIAL NO.:

10 537.864

APPLICANT:

Mattson *et al.*

FILING DATE:

06/07/2005

GROUP:

1647

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner initials*	Cite no.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/RMD/	CF	SUDA <i>et al.</i> , "Modulations of Osteoclast Differentiation", <i>Endocrine Reviews</i> , 13(1) :66-80 (1992)	
	CG	SUDA <i>et al.</i> , "Modulations of Osteoclast Differentiation: Update 1995", <i>Endocrine Reviews</i> , 4(1) :266-270 (1995)	
	CH	SUDA <i>et al.</i> , "Modulations of Osteoclast Differentiation by Local Factors". <i>Bone</i> , 17(2, Supp.) :87S-91S (1995)	
	CI	TAKAHASHI <i>et al.</i> , "A New Member of Tumor Necrosis Factor Ligand Family, ODF/OPGL/TRANCE/RANKL, Regulates Osteoclast Differentiation and Function", <i>Biochemical and Biophysical Research Communications</i> , 256(3) :449-455 (1999)	
	CJ	TASHJIAN <i>et al.</i> , "Tumor Necrosis Factor- α (Cachectin) Stimulates Bone Resorption in Mouse Calvaria via a Prostaglandin-Mediated Mechanism", <i>Endocrinology</i> , 120(5) :2029-2036 (1987)	
	CK	THOMSON <i>et al.</i> , "Osteoblasts mediate interleukin 1 stimulation of bone resorption by rat osteoclasts", <i>J. Exp. Med.</i> , 164(1) :104-112 (1986)	
	CL	THOMSON <i>et al.</i> , "Tumor necrosis factors alpha and beta induce osteoblastic cells to stimulate osteoclastic bone resorption", <i>J. Immunol.</i> , 138(3) :775-779 (1987)	
	CM	TSUDA <i>et al.</i> , "Isolation of a Novel Cytokine from Human Fibroblasts That Specifically Inhibits Osteoclastogenesis", <i>Biochemical and Biophysical Research Communications</i> , 234(1) :137-142 (1997)	
	CN	WONG <i>et al.</i> , "TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells", <i>J. Biol. Chem.</i> , 272(40) :25190-25194 (1997)	
	CO	YASUDA <i>et al.</i> , "Identity of Osteoclastogenesis Inhibitory Factor (OCIF) and Osteoprotegerin (OPG): A Mechanism by which OPG/OCIF Inhibits Osteoclastogenesis <i>In Vitro</i> ", <i>Endocrinology</i> , 139(3) :1329-1337 (1998)	
/RMD/	CP	YASUDA <i>et al.</i> , "Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL". <i>Proc. Natl. Acad. Sci. USA</i> ; 95(7) :3597-3602 (1998)	

Examiner signature:

ALL REFERENCES CONSIDERED EXCEPT WHERE

Date considered:

LINED THROUGH /RMD/ (05/15/2008)

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.